Focused ultrasound enhances intratumoral penetration of a PSMA-targeted antibody in a murine prostate cancer model

Cancer treatments that rely on antibodies are among the most promising tools in modern medicine. These are large, specialized proteins designed to seek out and bind to specific markers on the surface of cancer cells, effectively tagging them for destruction by the body's immune system or delivering a toxic payload directly to the tumor. However, while these drugs work well for cancers circulating in the blood, they often struggle to reach their targets when the disease is packed into a solid lump of tissue. Solid tumors are not just bags of bad cells; they are dense, tightly packed structures with high internal pressure and a thick, fibrous network that acts like a physical barrier. This environment pushes fluids outward and blocks large molecules from drifting deep inside, meaning that even the most potent antibody might get stuck on the surface of a tumor, unable to penetrate the core where it is needed most.

Researchers at Seoul National University and its affiliated hospitals have investigated a way to break through this barrier using sound. They focused on prostate cancer, a common disease where the cells typically carry a specific protein on their surface called prostate-specific membrane antigen, or PSMA. This protein serves as a perfect target for a custom-made antibody known as HuJ591. The team asked a straightforward question: if they could use focused ultrasound, a technique that directs sound waves to a precise spot deep inside the body without cutting the skin, could they temporarily open up the tumor's defenses to let the antibody in? Their work suggests that the answer is yes, and that this method not only helps the drug enter but also keeps it there for a much longer time.

To test this idea, the scientists first had to create their own version of the antibody. They engineered a humanized form of HuJ591 in a laboratory setting, ensuring it was pure and capable of binding tightly to the PSMA protein. They confirmed that the antibody worked exactly as intended by testing it against prostate cancer cells in a dish, showing it could latch onto the target with high precision. With a reliable tool in hand, they moved to a living model. They grew prostate cancer tumors in mice, creating a scenario where the animals had two tumors: one on each side of their body. This setup allowed the researchers to treat one tumor with focused ultrasound while leaving the other untouched, using the untreated side as a direct comparison within the same animal.

The experiment began when the mice received an injection of the antibody, which had been tagged with a glowing marker so the researchers could track its movement. Immediately after the injection, the team applied focused ultrasound to just one of the two tumors. The sound waves were delivered at a specific intensity for a short duration, a process designed to create tiny, temporary openings in the blood vessels and the dense tissue surrounding the tumor cells without causing damage. The researchers then watched what happened over the next two weeks. Using a highly sensitive camera system, they observed that the tumor that had received the sound treatment accumulated far more of the glowing antibody than the untreated one. The difference was visible almost immediately and remained significant throughout the observation period.

Looking closer at the tissue itself, the team found that the sound waves had changed the distribution of the drug. In the tumors that did not receive ultrasound, the antibody mostly stayed near the blood vessels on the outer edges, failing to reach the center. In contrast, the tumors that were exposed to the sound waves showed the antibody penetrating deep into the core and spreading evenly throughout the tissue. This was not just a matter of getting more drug inside; it was also about how long it stayed there. When the researchers checked the tumors fourteen days later, the untreated ones had mostly cleared the antibody, but the treated tumors still held a significant amount of it. This prolonged retention suggests that the sound waves did more than just push the drug in; they may have altered the tumor's internal environment to hold onto the treatment for longer.

To confirm these visual observations with hard numbers, the scientists measured the actual amount of antibody present in the tumor tissue. Their tests showed that the concentration of the drug in the ultrasound-treated tumors was significantly higher than in the control tumors. This quantitative data matched the images, proving that the sound waves successfully delivered a larger dose of the therapeutic agent directly to the site of the disease. The study also explored how the sound waves affected the antibody's ability to move through a three-dimensional ball of cancer cells, which mimics the structure of a real tumor. In these models, the sound waves helped the antibody sink deeper into the cluster of cells, whereas without the sound, the drug remained largely on the surface.

The researchers noted that while the results are encouraging, they represent a proof of concept rather than a finished cure. The study demonstrated that the delivery method works, but it did not test whether this increased delivery actually led to more cancer cell death or tumor shrinkage in the mice. That is the next critical step. Furthermore, the experiments were conducted on a specific type of cancer cell line, and the complex environment of a human tumor might present additional challenges. Despite these limitations, the findings offer a clear path forward. By showing that focused ultrasound can temporarily and safely modify the physical barriers of a solid tumor, the study provides a potential way to make antibody-based therapies much more effective. If this approach can be refined and tested in more complex models, it could eventually allow doctors to treat difficult solid tumors with lower doses of drugs, reducing side effects while improving the chances of a successful outcome.